BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 8568310)

  • 21. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
    Mitchell DK; Ruben FL; Gravenstein S
    Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of institutionalized asthmatic children and patients with psychomotor retardation using live attenuated cold-adapted reassortment influenza A H1N1, H3N2 and B vaccines.
    Miyazaki C; Nakayama M; Tanaka Y; Kusuhara K; Okada K; Tokugawa K; Ueda K; Shibata R; Nishima S; Yamane N
    Vaccine; 1993; 11(8):853-8. PubMed ID: 8356846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults.
    Treanor JJ; Roth FK; Betts RF
    J Clin Microbiol; 1990 Mar; 28(3):596-9. PubMed ID: 2182673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA; Gaglani MJ; Kozinetz CA; Herschler GB; Fewlass C; Harvey D; Zimmerman N; Glezen WP
    Pediatrics; 2007 Sep; 120(3):e553-64. PubMed ID: 17698577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA; Cate TR; Nino D; Huggins LL; Six HR; Quarles JM; Couch RB
    J Infect Dis; 2001 Jan; 183(2):329-332. PubMed ID: 11110645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of live attenuated cold-adapted influenza B/Yamagata/16/88 reassortant virus vaccine in healthy adults.
    Treanor JJ; Betts RF
    J Infect Dis; 1993 Aug; 168(2):455-9. PubMed ID: 8335984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The evaluation of the reactogenicity and immunological activity of an inactivated 3-component influenza vaccine with an elevated hemagglutinin concentration in the inoculation dosage].
    Marinich IG; Shadrin AS; Naĭkhin AN; Ivannikov IuG; Kuznetsov NP; Karogodina VI; Shcherbinskaia AM; Voronina EG; Stepankovskaia LD; Eliseeva IV
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):58-61. PubMed ID: 1950267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children.
    Piedra PA; Glezen WP; Mbawuike I; Gruber WC; Baxter BD; Boland FJ; Byrd RW; Fan LL; Lewis JK; Rhodes LJ
    Vaccine; 1993; 11(7):718-24. PubMed ID: 8342319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine.
    Clements ML; Murphy BR
    J Clin Microbiol; 1986 Jan; 23(1):66-72. PubMed ID: 3700610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine.
    Johnson PR; Feldman S; Thompson JM; Mahoney JD; Wright PF
    J Med Virol; 1985 Dec; 17(4):325-35. PubMed ID: 4078559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients.
    Van Hoecke C; Prikazsky V; Utö I; Menschikowski C
    Gerontology; 1996; 42(4):190-8. PubMed ID: 8832266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.
    Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M
    JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.